8-K: Nexalin Technology Announces $5.0 Million Public Offering of Common Stock

Nexalin Technology, Inc. has announced the pricing of a $5.0 million underwritten public offering of 3,850,000 shares of its common stock at $1.30 per share.

Summary

• Nexalin Technology, Inc. has announced the pricing of an underwritten public offering.
• The offering consists of 3,850,000 shares of common stock priced at $1.30 per share.
• The gross proceeds to Nexalin are expected to be approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.
• The offering is expected to close on or about May 6, 2025, subject to customary closing conditions.
• The underwriters have been granted a 45-day option to purchase up to 577,500 additional shares of common stock.
• Maxim Group LLC is acting as the sole book-running manager for the offering.
• Nexalin intends to use the net proceeds for working capital and other general corporate purposes, including sales and marketing activities, product development, and capital expenditures.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is securing additional funding, which should enable growth. However, the need for funding could also indicate existing financial pressures.

Positives

• The public offering is expected to provide Nexalin with approximately $5.0 million in gross proceeds.
• The funds are intended to be used for working capital, sales and marketing, product development, and capital expenditures, which could support the company's growth initiatives.

Risks

• The closing of the offering is subject to customary closing conditions and may not occur as expected or at all.
• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

Future Outlook

Nexalin intends to use the net proceeds from the offering for working capital and other general corporate purposes, including sales and marketing activities, product development and capital expenditures.

Industry Context

Nexalin operates in the neurostimulation and mental health technology sector, which is experiencing growth due to the increasing prevalence of mental health disorders and the demand for innovative treatment options. This offering could allow them to expand their market presence.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from increased investment in sales and marketing, product development, and capital expenditures.
• Customers may benefit from product development.

Next Steps

• The offering is expected to close on or about May 6, 2025, subject to customary closing conditions.
• Nexalin will file a final prospectus supplement and accompanying prospectus with the SEC.
• Nexalin will use the net proceeds from the offering for working capital and other general corporate purposes.

Key Dates

Keywords

public offering, common stock, Nexalin Technology, Maxim Group LLC, underwriting, capital raise, neurostimulation, mental health